Brown LG - Search Results

1

RNA Splicing Factors SRRM3 and SRRM4 Distinguish Molecular Phenotypes of Castration-Resistant Neuroendocrine Prostate Cancer.

Labrecque MP, Brown LG, Coleman IM, Lakely B, Brady NJ, Lee JK, Nguyen HM, Li D, Hanratty B, Haffner MC, Rickman DS, True LD, Lin DW, Lam HM, Alumkal JJ, Corey E, Nelson PS, Morrissey C. Labrecque MP, et al. Among authors: brown lg. Cancer Res. 2021 Sep 15;81(18):4736-4750. doi: 10.1158/0008-5472.CAN-21-0307. Epub 2021 Jul 26. Cancer Res. 2021. PMID: 34312180 Free PMC article.

2

LNCaP produces both putative zymogen and inactive, free form of prostate-specific antigen.

Corey E, Brown LG, Corey MJ, Buhler KR, Vessella RL. Corey E, et al. Among authors: brown lg. Prostate. 1998 May;35(2):135-43. doi: 10.1002/(sici)1097-0045(19980501)35:2<135::aid-pros7>3.0.co;2-i. Prostate. 1998. PMID: 9568677

3

Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol.

Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL. Corey E, et al. Among authors: brown lg. Clin Cancer Res. 2002 Apr;8(4):1003-7. Clin Cancer Res. 2002. PMID: 11948106

4

Establishment and characterization of osseous prostate cancer models: intra-tibial injection of human prostate cancer cells.

Corey E, Quinn JE, Bladou F, Brown LG, Roudier MP, Brown JM, Buhler KR, Vessella RL. Corey E, et al. Among authors: brown lg, brown jm. Prostate. 2002 Jun 1;52(1):20-33. doi: 10.1002/pros.10091. Prostate. 2002. PMID: 11992617

5

Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer.

Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS, Vessella RL. Corey E, et al. Among authors: brown lg. Clin Cancer Res. 2003 Jan;9(1):295-306. Clin Cancer Res. 2003. PMID: 12538482

6

Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function.

Brubaker KD, Vessella RL, Brown LG, Corey E. Brubaker KD, et al. Among authors: brown lg. Prostate. 2003 Jun 15;56(1):13-22. doi: 10.1002/pros.10233. Prostate. 2003. PMID: 12746842

7

Bone morphogenetic protein signaling in prostate cancer cell lines.

Brubaker KD, Corey E, Brown LG, Vessella RL. Brubaker KD, et al. Among authors: brown lg. J Cell Biochem. 2004 Jan 1;91(1):151-60. doi: 10.1002/jcb.10679. J Cell Biochem. 2004. PMID: 14689587

8

Metastases of prostate cancer express estrogen receptor-beta.

Lai JS, Brown LG, True LD, Hawley SJ, Etzioni RB, Higano CS, Ho SM, Vessella RL, Corey E. Lai JS, et al. Among authors: brown lg. Urology. 2004 Oct;64(4):814-20. doi: 10.1016/j.urology.2004.05.036. Urology. 2004. PMID: 15491740

9

Osteoprotegerin in prostate cancer bone metastasis.

Corey E, Brown LG, Kiefer JA, Quinn JE, Pitts TE, Blair JM, Vessella RL. Corey E, et al. Among authors: brown lg. Cancer Res. 2005 Mar 1;65(5):1710-8. doi: 10.1158/0008-5472.CAN-04-2033. Cancer Res. 2005. PMID: 15753366

10

Comparison of Fc-osteoprotegerin and zoledronic acid activities suggests that zoledronic acid inhibits prostate cancer in bone by indirect mechanisms.

Quinn JE, Brown LG, Zhang J, Keller ET, Vessella RL, Corey E. Quinn JE, et al. Among authors: brown lg. Prostate Cancer Prostatic Dis. 2005;8(3):253-9. doi: 10.1038/sj.pcan.4500815. Prostate Cancer Prostatic Dis. 2005. PMID: 15999121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

210 results

Search Page